EQS-News
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform - Seite 2
Under the terms of the agreement, Heidelberg Pharma has an exclusive option to license the platform, which can be used to develop immunostimulatory ADCs.
The agreement was signed by the subsidiary Heidelberg Pharma Research GmbH and by The Research Foundation for The State University of New York on behalf of Binghamton University.
About Heidelberg Pharma's proprietary ATAC technology
Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. ATACs are ADCs whose active
ingredient is the mushroom toxin Amanitin. Amanitin inhibits mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical
testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.
About Heidelberg Pharma
Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary ATAC technology and to advance the biological mode of
action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the Company’s own therapeutic ATACs as well as in third-party collaborations.
The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma. Further ATAC candidates are being developed against different targets such as CD37, PSMA or GCC each in the
indications non-Hodgkin's lymphoma, metastatic castration-resistant prostate cancer or gastrointestinal tumors such as colorectal cancer.
Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at http://www.heidelberg-pharma.com/.
ATAC is a registered trademark of Heidelberg Pharma Research GmbH in the EU and the USA.
About Binghamton University
Binghamton University, also known as the State University of New York at Binghamton, is one of four doctoral granting research universities in the SUNY system. It is ranked as an “R1” university
according to the Carnegie classification, with annual research expenditures exceeding $50 million. The School of Pharmacy and Pharmaceutical Sciences, a research-intensive pharmacy school
established in 2016, has rapidly become a hub of health-sciences research for Binghamton University and the Southern Tier of New York.